157 related articles for article (PubMed ID: 9096590)
1. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
2. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
[TBL] [Abstract][Full Text] [Related]
4. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rare p53 mutants from carcinogen-treated albumin-simian virus 40 T-antigen transgenic rats.
Haas MJ; Pitot HC
Mol Carcinog; 1998 Feb; 21(2):128-34. PubMed ID: 9496913
[TBL] [Abstract][Full Text] [Related]
6. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.
Hsu IC; Metcalf RA; Sun T; Welsh JA; Wang NJ; Harris CC
Nature; 1991 Apr; 350(6317):427-8. PubMed ID: 1849234
[TBL] [Abstract][Full Text] [Related]
7. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
8. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.
Hsia CC; Nakashima Y; Thorgeirsson SS; Harris CC; Minemura M; Momosaki S; Wang NJ; Tabor E
Oncol Rep; 2000; 7(2):353-6. PubMed ID: 10671685
[TBL] [Abstract][Full Text] [Related]
9. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
[TBL] [Abstract][Full Text] [Related]
11. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation.
Huang LR; Hsu HC
Cancer Res; 1995 Oct; 55(20):4717-21. PubMed ID: 7553654
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
13. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
Nishida N; Fukuda Y; Kokuryu H; Toguchida J; Yandell DW; Ikenega M; Imura H; Ishizaki K
Cancer Res; 1993 Jan; 53(2):368-72. PubMed ID: 8093350
[TBL] [Abstract][Full Text] [Related]
14. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.
Bressac B; Kew M; Wands J; Ozturk M
Nature; 1991 Apr; 350(6317):429-31. PubMed ID: 1672732
[TBL] [Abstract][Full Text] [Related]
15. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
16. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.
Yuwen H; Hsia CC; Nakashima Y; Evangelista A; Tabor E
Biochem Biophys Res Commun; 1997 May; 234(1):194-7. PubMed ID: 9168988
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines.
Hosono S; Lee CS; Chou MJ; Yang CS; Shih CH
Oncogene; 1991 Feb; 6(2):237-43. PubMed ID: 1847999
[TBL] [Abstract][Full Text] [Related]
18. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation.
Volkmann M; Hofmann WJ; Müller M; Räth U; Otto G; Zentgraf H; Galle PR
Oncogene; 1994 Jan; 9(1):195-204. PubMed ID: 8302580
[TBL] [Abstract][Full Text] [Related]
19. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
20. TP53 and hepatocellular carcinoma.
Puisieux A; Ozturk M
Pathol Biol (Paris); 1997 Dec; 45(10):864-70. PubMed ID: 9769950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
